State officials say 129 clinics and hospitals in Minnesota received drug products that could pose a possible meningitis risk to patients.
The products were prepared by the same Massachusetts pharmacy implicated in a national meningitis outbreak that has infected more than 200 people, killing 15 of them.
There are no confirmed cases of meningitis in patients who received other drugs prepared by the compounding pharmacy. But the FDA has identified two patients with fungal infections who did receive other drugs from the company.
The Minnesota Health Department is reaching out to all of the Minnesota facilities, according to Assistant State Epidemiologist Richard Danila.
"All we're doing is calling those clinics and saying did you see the FDA alert? Make sure you see and read it and follow their instructions. And we're not really telling them anything else. We're just kind of an extra safety step here to make sure everybody has seen the alert."
The FDA is urging providers to contact any patients who received injectable drugs sold by the Massachusetts pharmacy, particularly those